Neuroscience and Behavioral Physiology

, Volume 44, Issue 6, pp 631–639 | Cite as

Prognosis of Progressive Cognitive Deficit in Elderly Patients with Mild Cognitive Impairment Receiving Long-Term Treatment (3-year observations)

  • S. I. Gavrilova
  • I. V. Kolykhalov
  • Ya. B. Fedorova
  • Ya. B. Kalyn
  • N. D. Selezneva
  • A. V. Samorodov
  • S. N. Myasoedov
  • I. S. Boksha

The aim of the present work was to assess individual prognoses for Cerebrolysin treatment efficacy in mild cognitive impairment syndrome (MCIS) and to identify the most informative tests for prognosticating the development of dementia. A total of 53 patients with the amnestic type of MCIS were treated with Cerebrolysin for three years with regular neuropsychological and psychiatric clinical testing, with analysis of the results by nonparametric statistics, cluster analysis, and linear discriminant analysis. This combination of mathematical methods allowed decreases in cognitive functions to the level of dementia to be predicted. A “risk group” with a rapid decrease in cognitive functions and the threat of dementia was identified,i.e., a group with low therapeutic efficacy. Tests were ranked in terms of their prognostic value.


mild cognitive impairment syndrome dementia prognosis statistical methods 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    S. I. Gavrilova, Ya. B. Fedorova, I. F. Roshchina, and G. I. Korovaitseva, “Prognosis of mild cognitive deficit syndrome, data from a two-year prospective clinical study,” Nevrol. Psikhiat., 107, No. 1, 4–10 (2007).Google Scholar
  2. 2.
    S. I. Gavrilova, Ya. B. Fedorova, I. V. Kolykhalov, et al., “The therapeutic potential of Cerebrolysin in the preventative treatment of Alzheimer’s disease,” Nevrol. Psikhiat., No. 8, 24–28 (2008).Google Scholar
  3. 3.
    S. I. Gavrilova, I. V. Kolykhalov,Ya. B. Fedorova, et al., “The possibility of preventative treatment of Alzheimer’s disease: results of a 3-year prospective open comparative study of the efficacy and safety of courses of Cerebrolysin and Cavinton in elderly patients with mild cognitive deficit syndrome,” Nevrol. Psikhiat., 110, No. 1, 62–69 (2010).Google Scholar
  4. 4.
    G. I. Korovaitseva, T. V. Shcherbatykh, N. V. Selezneva, et al., “Genetic associations between alleles of the apolipoprotein E (ApoE) gene and different forms of Alzheimer’s disease,” Genetika, 37, No. 4, 529–535 (2001).PubMedGoogle Scholar
  5. 5.
    S. A. Sudakov, Cluster Analysis in Psychiatry and Clinical Psychology [in Russian], A. S. Tiganov (ed.), MIA, Moscow (2010).Google Scholar
  6. 6.
    X. A. Alvarez, V. R. Lonbardi, L. Corzo, et al., “Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects,” J. Neural Transm., 59, Supplement 1, 315–328 (2000).Google Scholar
  7. 7.
    X. A. Alvarez, R. Cacabelos, M. Laredo, et al., “24-week, doubleblind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease,” Eur. J. Neurosci., 13, No. 1, 43–54 (2006).CrossRefGoogle Scholar
  8. 8.
    H. Brodaty, M. Gresham, and G. Luscombe, “The Prince Henry hospital dementia caregivers’ training programme,” Int. J. Ger. Psych., 12, No. 2, 183–192 (1997).CrossRefGoogle Scholar
  9. 9.
    R. J. Caselli, A. C. Dueck, D. Osborne, et al., “Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect,” New Eng. J. Med., 361, No. 3, 255–263 (2009).PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Ch.-Y. Chiu, J. Douglas, and X. Li, “Cluster analysis for cognitive diagnosis: Theory and applications,” Psycometrika, 74, No. 4, 633–665 (2009).CrossRefGoogle Scholar
  11. 11.
    A. Collie, C. Myers, G. Schnirman, et al., “Selectively impaired associative learning in older people with cognitive decline,” J. Cogn. Neurosci., 14, 484–492 (2002).PubMedCrossRefGoogle Scholar
  12. 12.
    C. A. De Jager, “Changes over time in memory, processing speed and cock drawing tests help to discriminate between vascular cognitive impairment, mild cognitive impairment and Alzheimer’s disease,” Neurol. Res., 26, 481–487 (2004).PubMedCrossRefGoogle Scholar
  13. 13.
    C. A. De Jager, A. C. Schrijnemaekers, T. E. Honey, and M. M. Budge, “Detection of MCI in the clinic: Evaluation of the sensitivity and specificity of a computerised test battery: the Hopkins Verbal Learning Test and the MMSE,” Age Ageing, 38, No. 4, 455–460 (2009).PubMedCrossRefGoogle Scholar
  14. 14.
    B. Dubois, A. Slachevsky, I. Litvan, and B. Pillon, “The FAB: A frontal assessment battery at bedside,” Neurology, 55, 1621–1626 (2000).PubMedCrossRefGoogle Scholar
  15. 15.
    M. F. Folstein, S. E. Folstein, and P. R. McHugh, “Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician,” J. Psychiatr. Res., 12, 189–198 (1975).PubMedCrossRefGoogle Scholar
  16. 16.
    E. J. Golob, R. Irimajiri, and A. Starr, “Auditory cortical activity in amnestic mild cognitive impairment: Relationship to subtype and conversion to dementia,” Brain, 130, 740–752 (2007).PubMedCrossRefGoogle Scholar
  17. 17.
    V. Hachinski, “Cerebral blood flow differentiation of Alzheimer’s disease from multi-infarct dementia,” in: Alzheimer’s Disease: Senile Dementia and Related Disorders, R. Katzman, R. D. Terry, and K. L. Bick (eds.), Raven Press, New York (1978), pp. 97–104.Google Scholar
  18. 18.
    M. Hamilton, “A rating scale for depression,” J. Neurol. Neurosurg. Psychiatry, 23, 56–62 (1960).PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    E. F. Kaplan, H. Goodglass, and S. Weintraub, The Boston Naming Test, Lea & Febiger, Philadelphia (1983), 2nd ed.Google Scholar
  20. 20.
    S. Mattis, “Mental status examination for organic mental syndrome in the elderly patient,” in: Geriatric Psychiatry, L. Bellack and T. B. Karusu (eds.), Grune & Stratton, New York (1976), pp. 77–121.Google Scholar
  21. 21.
    J. C. Morris, “The Clinical Dementia Rating (CDR): current version and scoring rules,” Neurology, 43, No. 11, 2412–2414 (1993).PubMedCrossRefGoogle Scholar
  22. 22.
    R. C. Petersen, G. E. Smith, S. C. Waring, et al., “Mild cognitive impairment: Clinical characterization and outcome,” Arch. Neurol., 56, No. 3, 303–308 (1999).PubMedCrossRefGoogle Scholar
  23. 23.
    R. C. Petersen, “Mild cognitive impairment as a diagnostic entity,” J. Intern. Med., 256, No. 3, 183–194 (2004).PubMedCrossRefGoogle Scholar
  24. 24.
    G. L. Plosker and S. Gauthier, “Spotlight on cerebrolysin in dementia,” CNS Drugs, 24, No. 3, 263–266 (2010).PubMedCrossRefGoogle Scholar
  25. 25.
    B. Reisberg, S. H. Ferris, M. J. de Leon, and T. Crook, “Global Deterioration Scale (GDS),” Psychopharm. Bull., 24, No. 4, 661–663 (1988).Google Scholar
  26. 26.
    K. Schmidtke and S. Hermeneit, “High rate of conversion to Alzheimer’s disease in a cohort of amnestic MCI patients,” Int. Psychogeriatr., 20, 96–108 (2008).PubMedCrossRefGoogle Scholar
  27. 27.
    K. I. Shulman, R. Shedletsky, and I. L. Silver, “The challenge of time: clock-drawing and cognitive function in the elderly,” Int. J. Geriatr. Psychiatr., No. 1, 135–140 (1986).Google Scholar
  28. 28.
    T. Sunderland, J. L. Hill, A. M. Mellow, et al., “Clock drawing in Alzheimer’s disease: A novel measure of dementia severity,” J. Am. Geriatr. Soc., 37, No. 8, 725–729 (1989).PubMedGoogle Scholar
  29. 29.
    D. Wechsler, Wechsler Adult Intelligence Scale – Revised, Psychological Corporation, New York (1981).Google Scholar
  30. 30.
    Z. H. Wei, G. B. He, H. Wang, et al., “Meta-analysis: the efficacy of nootropic agent cerebrolysin in the treatment of Alzheimer’s disease,” J. Neural Transm., 114, No. 5, 629–634 (2007).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • S. I. Gavrilova
    • 1
  • I. V. Kolykhalov
    • 1
  • Ya. B. Fedorova
    • 1
  • Ya. B. Kalyn
    • 1
  • N. D. Selezneva
    • 1
  • A. V. Samorodov
    • 2
  • S. N. Myasoedov
    • 1
  • I. S. Boksha
    • 1
  1. 1.Scientific Center for Mental HealthRussian Academy of Medical SciencesMoscowRussia
  2. 2.Bauman Moscow State Technical UniversityMoscowRussia

Personalised recommendations